Drug intelligence / Profile preview

ABV-1503

Development stage: Preclinical
Lead developer: BioLite
Modality: Small Molecules
Administration: Oral

Overview

ABV-1503 is an investigational oral botanical fixed-dose combination being developed for **chronic lymphocytic leukemia**. American BriVision's SEC disclosures describe it as an anti-cancer botanical drug originating with BioLite and identify epigallocatechin gallate and curcumin as its principal active ingredients; the program was being prepared for a U.S. IND-supported clinical study rather than marketed as an approved therapy. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/abvcsuper8k.htm))

Beyond the preview

Go deeper on ABV-1503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABV-1503.

Explore the full profile